Cerenome is trading at $1.80, up 5.88% on November 2, 2026, with no clear company-specific announcement explaining the move.
- The latest company news was October 29, when Cerenome announced completing enrollment in its Phase 2 ReSPECT-GBM trial; topline data is expected in mid-2027.
- The S&P 500 was up 0.56%, the Nasdaq 0.78%, and the Dow 0.98%. Broader market sentiment may be contributing, but no direct link to Cerenome’s gain is confirmed.
- Volume and trading activity details are unavailable.